Challenges of LC-MS/MS ethyl glucuronide analysis in abstinence monitoring of liver transplant candidates.


Journal

Clinical chemistry and laboratory medicine
ISSN: 1437-4331
Titre abrégé: Clin Chem Lab Med
Pays: Germany
ID NLM: 9806306

Informations de publication

Date de publication:
28 07 2020
Historique:
received: 18 12 2019
accepted: 31 01 2020
pubmed: 1 3 2020
medline: 18 8 2021
entrez: 1 3 2020
Statut: ppublish

Résumé

Background Urinary ethyl glucuronide (EtG) has emerged as the biomarker of choice for alcohol abstinence monitoring in forensic toxicology and is now used in the listing decision process for liver transplantations (LTs) in the German transplant program. However, EtG analysis in this patient group is challenging due to severely impaired liver function, renal failure, co-morbidities and multidrug regimens. The aim of our study was to evaluate liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based EtG analysis for a precise abstinence monitoring in transplant candidates. Methods EtG and ethyl sulfate (EtS) were analyzed by a commercial LC-MS/MS assay in 1787 spot urine samples of 807 patients (>85% from the Department of Hepatology) using a combination of quantifier and two qualifier mass transitions for each analyte. Influences of bacterial contamination, kidney and liver function were investigated. Results Two hundred and sixty-four urine samples had elevated (≥0.5 mg/L) EtG concentrations when only analyzing one quantifier mass transition. Eleven results (4.2%) were found to be false positive after combining three mass transitions for EtG quantification and verification with parallel analysis of EtS. Decreased kidney function was associated with a significantly higher rate of positive EtG samples. One of the false positive results was caused by bacterial metabolism. Conclusions Multimorbid pre-transplant patients have a high risk of individual analytical disturbances of EtG results obtained by LC-MS/MS. Therefore, EtG and EtS should always be measured by a combination of one quantifier and two qualifiers each and evaluated together.

Identifiants

pubmed: 32112697
doi: 10.1515/cclm-2019-1302
pii: cclm-2019-1302
doi:

Substances chimiques

Biomarkers 0
Glucuronates 0
ethyl glucuronide 17685-04-0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1265-1270

Références

Tacke F, Kroy DC, Barreiros AP, Neumann UP. Liver transplantation in Germany. Liver Transplant 2016;22:1136–42.
Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the united states. Gastroenterology 2015;148:547–55.
Adam R, Karam V, Delvart V, O’Grady J, Mirza D, Klempnauer J, et al. Evolution of indications and results of liver transplantation in Europe. a report from the European Liver Transplant Registry (ELTR). J Hepatol 2012;57:675–88.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: liver transplantation. J Hepatol 2016;64:433–85.
Erim Y, Böttcher M, Dahmen U, Beck O, Broelsch CE, Helander A. Urinary ethyl glucuronide testing detects alcohol consumption in alcoholic liver disease patients awaiting liver transplantation. Liver Transplant 2007;13:757–61.
Staufer K, Andresen H, Vettorazzi E, Tobias N, Nashan B, Sterneck M. Urinary ethyl glucuronide as a novel screening tool in patients pre- and post-liver transplantation improves detection of alcohol consumption. Hepatology 2011;54:1640–9.
Richtlinien zur Organtransplantation gem. §16 TPG (German transplantation guidelines). Dtsch Arztebl 2016;113:A–1947/B-1635/C-1623.
Jatlow PI, Agro A, Wu R, Nadim H, Toll BA, Ralevski E, et al. Ethyl glucuronide and ethyl sulfate assays in clinical trials, interpretation, and limitations: results of a dose ranging alcohol challenge study and 2 clinical trials. Alcohol Clin Exp Res 2014;38:2056–65.
Helander A, Bottcher M, Fehr C, Dahmen N, Beck O. Detection times for urinary ethyl glucuronide and ethyl sulfate in heavy drinkers during alcohol detoxification. Alcohol Alcohol 2008;44:55–61.
Helander A, Beck O. Mass spectrometric identification of ethyl sulfate as an ethanol metabolite in humans. Clin Chem 2004;50:936–7.
Becker S, Brauer R, Böttcher M, Thiery J, Ceglarek U. Evaluation of a commercial LC-MS/MS assay for the quantification of ethyl glucuronide in urine for alcohol intake monitoring. J Lab Med 2015;39:159–63.
Stephanson N, Dahl H, Helander A, Beck O. Direct quantification of ethyl glucuronide in clinical urine samples by liquid chromatography-mass spectrometry. Ther Drug Monit 2002;24:645–51.
Helander A, Kenan N, Beck O. Comparison of analytical approaches for liquid chromatography/mass spectrometry determination of the alcohol biomarker ethyl glucuronide in urine. Rapid Commun Mass Spectrom 2010;24:1737–43.
Helander A, Olsson I, Dahl H. Postcollection synthesis of ethyl glucuronide by bacteria in urine may cause false identification of alcohol consumption. Clin Chem 2007;53: 1855–7.
Høiseth G, Nordal K, Pettersen E, Mørland J. Prolonged urinary detection times of EtG and EtS in patients with decreased renal function. Alcohol Clin Exp Res 2012;36:1148–51.
Fraser AD, Zamecnik J. Impact of lowering the screening and confirmation cutoff values for urine drug testing based on dilution indicators. Ther Drug Monit 2003;25:723–7.
Helander A, Dahl H. Urinary tract infection: a risk factor for false-negative urinary ethyl glucuronide but not ethyl sulfate in the detection of recent alcohol consumption. Clin Chem 2005;51:1728–30.
Baranowski S, Serr A, Thierauf A, Weinmann W, Groβe Perdekamp M, Wurst FM, et al. In vitro study of bacterial degradation of ethyl glucuronide and ethyl sulphate. Int J Legal Med 2008;122:389–93.
Musshoff F, Albermann E, Madea B. Ethyl glucuronide and ethyl sulfate in urine after consumption of various beverages and foods – misleading results? Int J Legal Med 2010;124:623–30.
Høiseth G, Yttredal B, Karinen R, Gjerde H, Christophersen A. Levels of ethyl glucuronide and ethyl sulfate in oral fluid, blood, and urine after use of mouthwash and ingestion of nonalcoholic wine. J Anal Toxicol 2010;34:84–8.

Auteurs

Mitja L Heinemann (ML)

Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital Leipzig, Liebigstr. 27, 04103 Leipzig, Germany, Phone: +493419722200, Fax: +493419722209.

Louis Elsing (L)

Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital Leipzig, Leipzig, Germany.

Thorsten Kaiser (T)

Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital Leipzig, Leipzig, Germany.

Michael Boettcher (M)

MVZ Labor Dessau GmbH, Dessau, Germany.

Adam Herber (A)

Section of Hepatology, University Hospital Leipzig, Leipzig, Germany.

Daniel Seehofer (D)

Clinic and Policlinic of Visceral-, Transplant-, Thoracic- and Vascular Surgery, University Hospital Leipzig, Leipzig, Germany.

Thomas Berg (T)

Section of Hepatology, University Hospital Leipzig, Leipzig, Germany.

Uta Ceglarek (U)

Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital Leipzig, Leipzig, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH